
CLAIMS

1. Use of an anti-HER3 antibody-drug conjugate in the manufacture of a medicament for the treatment of EGFR-TKI-resistant non-small cell lung cancer, wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence represented by SEQ ID NO:1, CDRH2 consisting of the amino acid sequence represented by SEQ ID NO:2, and CDRH3 consisting of the amino acid sequence represented by SEQ ID NO:3, and a lightchain comprising CDRL1 consisting of the amino acid sequence represented by SEQ ID NO:4, CDRL2 consisting of the amino acid sequence represented by SEQ ID NO:5, and CDRL3 consisting of the amino acid sequence represented by SEQ ID NO:6, wherein the EGFR-TKI-resistant non-small cell lung cancer is resistant to Osimertinib, and wherein the anti-HER3 antibody-drug conjugate is an anti-HER3 antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein A in the formula represents the connecting position to the anti-HER3 antibody,

is conjugated to the anti-HER3 antibody via a

thioether bond.

2. The use according to claim 1, wherein the non-small cell lung cancer is EGFR T790M mutation-negative non-small cell lung cancer.

3. The use according to claim 1 or 2, wherein the EGFR-TKI-resistant non-small cell lung cancer is further resistant to gefitinib, erlotinib, or afatinib.

4. The use according to claim 1 or 2, wherein the EGFR-TKI-resistant non-small cell lung cancer is further resistant to gefitinib or erlotinib.


5. The use according to any one of claims 1 to 4, wherein the non-small cell lung cancer expresses HER3.

6. The use according to any one of claims 1 to 5, wherein the anti-HER3 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO:7, and a light chain comprising a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO:8.

7. The use according to any one of claims 1 to 6, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence represented by SEQ ID NO:9, and a light chain consisting ofthe amino acid sequence represented by SEQ ID NO:10.


8. The use according to claim 7, wherein the anti-HER3 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.

9. The use according to any one of claims 1 to 8, wherein the anti-HER3 antibody-drug conjugate is an anti-HER3 antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein the drug-linker in the formula is conjugated to the anti-HER3 antibody via a thioether bond, and n is the average number of units of the drug-linker conjugated per antibody molecule.

10. The use according to any one of claims 1 to 8, wherein the anti-HER3 antibody-drug conjugate is an anti-HER3 antibody-drug conjugate in which a drug-linker represented by the following formula:



wherein the drug-linker in the formula is conjugated to the anti-HER3 antibody via a thioether bond, and n is a drug to antibody ratio.

11. The use according to any one of claims 1 to 9, wherein the average number of units of the drug-linker conjugated per antibody molecule in the anti-HER3 antibody- drug conjugate is in the range of 2 to 8.

12. The use according to any one of claims 1 to 9, wherein the average number of units of the drug-linker conjugated per antibody molecule in the anti-HER3 antibody- drug conjugate is in the range of 3 to 8.

13. The use according to any one of claims 1 to 9, wherein the average number of units of the drug-linker conjugated per antibody molecule in the anti-HER3 antibody- drug conjugate is in the range of 7 to 8.

14. The use according to any one of claims 1 to 9, wherein the average number of units of the drug-linker conjugated per antibody molecule in the anti-HER3

antibody-drug conjugate is in the range of 7.5 to 8.

15. The use according to any one of claims 1 to 14, wherein the anti-HER3 antibody-drug conjugate is administered in combination with a second drug.

16. The use according to claim 15, wherein the second drug is gefitinib, erlotinib, afatinib, or osimertinib.

17. The use according to claim 16, wherein the second drug is erlotinib.

18. The use according to claim 16, wherein the second drug is osimertinib.